06:20 AM EDT, 07/17/2024 (MT Newswires) -- Adverum Biotechnologies ( ADVM ) said Wednesday that a 26-week interim analysis of its mid-stage trial of its novel gene therapy candidate, Ixo-vec, in patients with wet age-related macular degeneration showed the drug has a "potential best-in-class" product profile.

Among two sets of 29 patients each receiving different dosages of Ixo-vec, patients needed 76% to 83% of injections to treat the degeneration. The company said visual acuity and fluid control were also maintained at both dose levels.

Adverum said Ixo-vec was well tolerated at both doses, with all adverse events classified as either mild or moderate.

Price: 11.40, Change: +2.48, Percent Change: +27.80